Clinical trials: glp1 Agonist
Type 2 Diabetes Mellitus
Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial
This study aims to provide essential mechanistic insights into natriuretic and hemodynamic effects of SGLT2i and GLP-1RA agents in T2D patients.
- Trial name
- NATRIURETIC (NCT04535960)
- Testing
- Empagliflozin 25 MG + Liraglutide 1.8 MG, Liraglutide 1.8 MG + Empagliflozin 25 MG
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- University Health Network, Toronto
Alopecia
Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use
A single-center, open-label clinical study to evaluate whether a dietary supplement can reduce hair loss in women with GLP-1-associated telogen effluvium. Participants will use the supplement for 120 days.
- Trial name
- GLP-1 (NCT07783113)
- Testing
- Dietary Supplement for Hair Loss
- Where
- Brazil
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Farmoquimica S.A.
Diabetes Mellitus
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and…
- Trial name
- NCT02465515
- Testing
- Albiglutide 30 mg, Albiglutide 50 mg
- Where
- 607 sites in United States, Argentina and 26 more
- Volunteers
- 9,463 people
- Sponsor
- GlaxoSmithKline
Spinal Cord Injuries, Type 2 Diabetes
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition.
- Trial name
- NCT06706284
- Testing
- Semaglutide Injectable Product
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Marzieh Salehi
Diabetes Mellitus, Diabetic Kidney Disease
Basal Plus GLP1-ra on Glycemic Variability in CKD
To compare GLP-1 RA plus basal insulin (BGLP) versus basal-bolus (BB) insulin regimens on glycemic variability (GV) and time in range (TIR) in diabetes patients CKD stage 3-4
- Trial name
- NCT05218915
- Testing
- Dulaglutide, Insulin Degludec, Continuous glucose monitor
- Where
- Hong Kong
- Volunteers
- 95 people
- Sponsor
- Elaine Chow
Obesity Type 2 Diabetes Mellitus, Cardiovascular-kidney-metabolic Syndrome
Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare early treatment intensification strategies in adults with obesity, type 2 diabetes…
- Conditions
- Obesity Type 2 Diabetes Mellitus, Cardiovascular-kidney-metabolic Syndrome, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- NCT07566299
- Volunteers
- 118,805 people
- Sponsor
- Chung Shan Medical University
Type 2 Diabetes (T2D)
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR…
- Trial name
- China Soli-CGM (NCT06671587)
- Testing
- iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine)
- Where
- China
- Volunteers
- 678 people
- Sponsor
- Sanofi
Endocrinology, Diabetes, Type II
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable…
- Conditions
- Endocrinology, Diabetes, Type II, Obesity
- Trial name
- ARAY (NCT06851858)
- Testing
- AZD6234
- Where
- 18 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Type 1
A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes
The goal of this clinical trial is to learn if Empagliflozin and Semaglutide, individually and combined, added to Automated Insulin Delivery (AID) works to improve time-in-range in adults living with Type 1 Diabetes.
- Trial name
- SEMPA (NCT06894784)
- Testing
- Intervention Period 1: Semaglutide + Empagliflozin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Covid19, Myocardial Injury
Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19
With the results of this study the investigators aim to identify an effective treatment that will reduce morbidity and mortality of patients with symptomatic COVID-19 infection, which would in turn reduce the burden on the…
- Trial name
- SEMPATICO (NCT04615871)
- Testing
- semaglutide
- Where
- 10 sites in Brazil, Canada and 2 more
- Volunteers
- 400 people
- Sponsor
- Vladimír Džavík
Diabete Type 2
A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil
This is a Phase I, randomized, double-blind, placebo-controlled, single-dose study in healthy adult participants in Brazil to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of…
- Trial name
- BRIDGE-BR (NCT07518121)
- Testing
- Efsubaglutide Alfa Injection
- Where
- Brazil
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Alcohol Dependence, in Remission, Addiction, Alcohol
Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?
The study is a double-blinded, randomized, placebo-controlled, 26-weeks clinical trial. The objective of the trial is to investigate the effects of the GLP-1 receptor agonist Bydureon® (exenatide) vs.
- Trial name
- EXALT (NCT03232112)
- Testing
- Exenatide 2 MG Injection, BD PosiFlush (saline)
- Where
- Denmark
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Healthy Participants
A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations
The purpose of this study is to assess the relative bioavailability of a single dose AZD5004 in healthy participants, among 3 different oral tablet formulations.
- Trial name
- NCT06996886
- Testing
- AZD5004
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Lower Back Pain, Obesity (BMI>30)
Semaglutide for Low Back Pain
Low back pain is the leading cause of disability in the United States, and obesity is a major risk factor for its development. GLP-1 receptor agonists such as Semaglutide have emerged as effective weight loss agents that may also…
- Conditions
- Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
- Trial name
- NCT07731256
- Testing
- Semaglutide (administered by PDS290 pen-injector)
- Where
- 2 sites in United States
- Volunteers
- 250 people
- Sponsor
- Washington University School of Medicine
Dementia, Mild, Mild Cognitive Impairment
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluating the efficacy and safety of mazdutide in 420 participants with type 2 diabetes (T2D) and…
- Conditions
- Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes
- Trial name
- NCT07083154
- Testing
- Mazdutide
- Where
- 8 sites in China
- Volunteers
- 420 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Semaglutide-Induced Gastric Motility, Gastroparesis
Body Surface Gastric Mapping in Patients on Semaglutide
Glucagon-like receptor-1 agonists (GLP-1 RAs), such as Semaglutide (Ozempic), are a class of drugs used for glycemic control in diabetes, and for weight loss and management in obesity.
- Trial name
- NCT06401746
- Testing
- Gastric Alimetry
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- University of Western Sydney